Here are some more institutional ownership comparisons: Bacterin International... 13% Zinga... 35% Facebook... 36% Ford... 52% Dendreon... 59% Johnson and Johnson... 64% Apple... 65% Amazon... 67% Eli Lilly... 73% (Dyax Partner) Dyax... 78% Biogen... 90% (Dyax Parnter)
Name me another stock that has was trading in the $1.50 range within the past 12 month who has institutional ownership this high. HEAVY stealth accumulation has been going on in DYAX over the past year... no doubt all those post I've made in the past regarding those many mysterious days where DYAX was having 25-50% of its daily volume traded AH with no price movement was a sign of accumulation. Of course, their deeds were done at fixed prices (somehow) AH to keep from ramping the stock price during market hours as the volume during the day was simply not heavy enough to support the accumulation that was going on.
I'm projecting that the conclusion of Eli Lilly Phase III results on Ramucirumad will send DYAX to $5.50+ range in 2013. Double-digits by conclusion of 2015. Remember, it was just a few months ago that Eli Lilly was upgraded to BUY based on its Ramucirumad results thus far with GASTRIC cancer. What you must remember however, is that Eli Lilly actually has other phase III trials going on with Ramucirumad ... BREAST cancer trials, COLORECTAL cancer trials, LUNG cancer trials, and LIVER cancer trials.
DYAX will get royalties from ALL these. Plus, Eli Lilly is just ONE of MANY of DYAX partners. I'm waiting for the MS drug results in partnership with Biogen... DYAX already has Biogen's former Medical Research Director serving as their Chief Medical Officer.